Viking Therapeutics/$VKTX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
- Ticker
- $VKTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 65
- Headquarters
- San Diego, United States
- Website
- www.vikingtherapeutics.com
VKTX Metrics
BasicAdvanced
$3.2B
-
-$4.67
0.68
-
Price and volume
Market cap
$3.2B
Beta
0.68
52-week high
$43.15
52-week low
$25.77
Average daily volume
6.7M
Financial strength
Current ratio
4.72
Quick ratio
4.575
Long term debt to equity
0.01
Total debt to equity
0.01
Interest coverage (TTM)
-70,002.63%
Profitability
Management effectiveness
Return on assets (TTM)
-51.86%
Return on equity (TTM)
-88.85%
Valuation
Price to book
7.92
Price to tangible book (TTM)
7.92
Price to free cash flow (TTM)
-7.593
Free cash flow yield (TTM)
-13.17%
Free cash flow per share (TTM)
-3.652
Growth
Earnings per share change (TTM)
203.73%
3-year earnings per share growth (CAGR)
73.32%
10-year earnings per share growth (CAGR)
10.59%
What the Analysts think about VKTX
Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.
Analyst projections of the future price of Viking Therapeutics stock.
Bulls say / Bears say
VK2735 showed strong maintenance potential: patients retained up to 97% of prior weight loss on fortnightly dosing and up to 90% on monthly dosing, versus 61% after switching to placebo. Gastrointestinal adverse-event rates were comparable with placebo during the 12-week maintenance period. (Reuters, PR Newswire)
The same study reported about 22% weight loss after 33 weeks in an exploratory 17.5mg weekly group, with no plateau observed. That gives VK2735 a promising efficacy signal before the larger Phase 3 read-outs. (Reuters, PR Newswire)
Viking is progressing two fully enrolled injectable Phase 3 trials and plans to start two oral VK2735 Phase 3 trials in the fourth quarter of 2026. An effective tablet would give the company a second route to market and could differentiate it from injectable-only options. (Viking Therapeutics, Viking Therapeutics)
VK2735 remains an unapproved, late-stage asset: the injectable Phase 3 results are not expected until the second half of 2027. The oral programme also has a tolerability overhang, after about 20% of participants in its Phase 2 study discontinued because of adverse events. (The Motley Fool)
Viking is trying to enter a market led by Eli Lilly and Novo Nordisk, with other well-funded rivals also developing obesity treatments. Even good mid-stage results may not translate into meaningful market share if competitors offer stronger efficacy, safety, pricing or supply. (The Motley Fool, Stocktwits)
The company is spending heavily before it has product revenue: cash and short-term investments were about $502m at the end of June 2026, while the first-half net loss was about $286m. Continued Phase 3 spending could force another equity raise before pivotal data, diluting existing shareholders. (Viking Therapeutics, AInvest)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
VKTX Financial Performance
Revenues and expenses
VKTX Earnings Performance
Company profitability
Upcoming events
No upcoming events
VKTX News
AllArticlesVideos
Funds containing VKTX
AllEURGBPUSD
Fund name | Fund size | $VKTX weighting |
|---|---|---|
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.05% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.05% |
iShares MSCI World Small Cap$WSML | $9B | 0.03% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.03% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.